Insmed price target lowered to $226 from $230 at Guggenheim

Guggenheim analyst Vamil Divan lowered the firm’s price target on Insmed (INSM) to $226 from $230 and keeps a Buy rating on the shares. The firm’s target cut is largely driven by an increase in operating expense estimates and a “modest decrease” to its ex-U.S. Brinsupri revenue estimates, the analyst tells investors.